As part of the collaboration, TwinEdge will develop individual digital twins (“avatars”) of a collection of Diffuse large B-cell lymphoma (DLBCL) Patient Derived Xenograft (PDX) mouse models (provided by Crown Bioscience, Inc.), integrating molecular and dose-response data into mechanistic simulations. The multi-phase goal of the collaboration is to further elucidate HX009’s mechanism of action, model potential clinical performance across lymphoma patients, and explore MoA relevance beyond the initial DLBCL focus.
Traditional preclinical readouts often limit how deeply early efficacy and variability can be understood. By computationally testing across thousands of simulated patients, the programme will explore heterogeneity across lymphoma patient populations and biomarker-linked response patterns. These insights aim to refine patient-selection hypotheses, strengthen early translational evidence for HX009, and help optimise clinical path planning.
